Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
The holiday season provides the perfect opportunity to give thanks and to give back to youth who are facing challenges within our communities. In days of uncertainty, there are still people who are providing direction and mentoring to high-risk youth to help them succeed in spite of the unfortunate circumstances they may have encountered. Many studies indicate that a young person’s success can be greatly enhanced by an advocate or mentor — an adult who consistently helps a young person stay on track to graduate and make better life choices. Goodwill’s GoodGuides program is the source of many modern-day mentoring success stories.
The GoodGuides program provides mentoring to youth, ages 12–17, who are at risk of dropping out of school and/or falling into delinquency. The program helps them finish school, transition into the world of work and prepare for success by pairing them with trusted adult volunteer mentors. Mentors help youth overcome disadvantages such as failure in school due to poor grades or low attendance, or avoid delinquency due to issues such as abuse, disability, drug or alcohol dependence, family violence or gang membership.
To view the multimedia release go to:
http://www.multivu.com/players/English/7057252-goodwill-givegoodwill-campaign/
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced Accelrys Insight and Accelrys Insight for Excel, completing the roll-out of Accelrys’ next-generation cheminformatics suite and providing an interactive, collaborative environment for rapid and effective decision-making in drug discovery. Accelrys Insight and Accelrys Insight for Excel offer research scientists an entirely new way of accessing, visualizing and analyzing data that is locked in disparate locations across internal discovery teams and networked external partners, helping to lower long-standing barriers to bringing innovative therapeutics to market faster and more cost effectively.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62191-accelrys-insight-next-generation-decision-making-in-scientific-discovery
Millennium Health, a leading health solutions company, today announced the launch of the Drop Them Off campaign, in partnership with the Mark Wahlberg Youth Foundation and the Partnership for Drug-Free Kids’ Medicine Abuse Project. Designed to increase awareness of the problem of youth misuse and abuse of prescription medicine, the campaign intends to educate parents and youth on how to properly use, store, and dispose of prescription medications by dropping them off at appropriate collection sites among other methods, to reduce access and opportunity for misuse or abuse. Educational content will be available online (www.DropThemOff.com) and through curriculum delivered through the Mark Wahlberg Youth Foundation’s community-based partners. Millennium Health is a Silver Sponsor of the Medicine Abuse Project, a campaign that aims to prevent half a million teens from abusing medicine by 2017.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7071752-millennium-health-drop-them-off/
The U.S. Food and Drug Administration (FDA) is alerting pregnant women about the risks of listeriosis, a foodborne disease that can severely affect a pregnant women and her unborn child.
Listeria can affect all races and ethnic groups, but pregnant women are 10 times more likely than other healthy adults to get listeriosis due to hormonal changes that affect the immune system during pregnancy. Pregnant Hispanic women are about 24 times more likely than the general population to get listeriosis. A pregnant mother may pass Listeria onto her unborn baby without even knowing it because she doesn’t feel sick at all, yet the disease can lead to miscarriage, stillbirth, premature labor, the delivery of a low birthweight infant, a wide range of health problems for a newborn, or even infant death.
To view the multimedia release go to:
https://www.multivu.com/players/English/7953451-fda-listeriosis-prevention-pregnant-women/
Dune Medical Devices, Inc., announced today that its breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, the MarginProbe System, has received Premarket Approval (PMA) by the United States Food and Drug Administration. The technology significantly improves surgeons’ ability to intra-operatively identify
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, has announced the availability of an extensive set of advanced predictive sciences applications and services. These integrated capabilities enable drug discovery teams to investigate and evaluate hypotheses about the chemical or biological behavior of molecules of therapeutic interest in silico prior to costly experimentation. Accelrys predictive sciences leverages the open, scientifically aware Accelrys Enterprise Platform to deliver an advanced scientific decision support environment that reduces time and expense, improves quality, enhances collaboration and accelerates innovation in bringing new drugs to market.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62190-accelrys-offers-integrated-predictive-sciences-solutions-faster-innovation
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
Allergan, Inc. (NYSE: AGN), the makers of LATISSE® (bimatoprost ophthalmic solution) 0.03%, announced today the launch of the LATISSE® Wishes Challenge campaign. Inspired by the tradition of blowing on an eyelash to make wishes come true, lifestyle designer Kathy Ireland, professional ballroom dancer Chelsie Hightower and style guide Bobbie Thomas will each lead teams of LATISSE® users from across the country who are challenged to raise more than a quarter of a million dollars for the Make-A-Wish Foundation, a nonprofit organization dedicated to granting the wishes of children with life-threatening medical conditions. LATISSE® solution is the first and only prescription treatment approved by the U.S. Food and Drug Administration (FDA) to grow lashes longer, fuller and darker for those with inadequate or not enough lashes (eyelash hypotrichosis).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/latisse/43354/
Abbott announced today the U.S. Food and Drug Administration approval and launch of the iDesign Advanced WaveScan Studio System. The system acts as the "brain" of the LASIK procedure, generating a high-definition scan that measures and maps irregularities of the eye that may impact vision. From these measurements, the iDesign System creates an accurate and personalized LASIK treatment plan based on the unique "blueprint" of each person’s eyes.
The iDesign System captures more than 1,200 micro readings of the eye, as well as identifying the shape of the cornea, its curvature, how light passes through the eye and pupil diameter under different lighting conditions – all in one, three-second scan that can be used to precisely correct vision.
The development of the sensor technology within the iDesign System was the result of an earlier discovery by Abbott scientists, which NASA used to accurately measure and shape the mirrors in the James Webb Space Telescope to ensure it will transmit high resolution images of deep space back to earth. The telescope is scheduled to launch in 2018.
To view the Multimedia News Release, please go to http://www.multivu.com/players/English/7571951-abbott-idesign-system-3-d-eye-map/
California News on Ibogaine Treatment 20 Feb, 2004 - BAY AREA (KRON 4) - Drug addiction has been the plague of modern America. But that could now change forever. What started as a rumor may now actually be an incredible breakthrough in the battle against addictions of all kinds. Features Dr. Deborah Mash who says she is going to submit to FDA her data gathered in her St. Kitts clinic.
Some addicts may have a long history of ADHD
btw. The history of ADHD is often said to start with George Still 1902. Actually it starts already 1798 with George Crichton:
http://adhd-npf.com/adhd-history/
Just back from rehab, Mary Rose returns to her regular hang-out in pursuit of her “would-be” soul mate, Ryan. She is devastated when he shows up with another girl… and not just any girl either… a really pretty hippie girl, who is older, and maybe even cooler. The True Diary of Mary Rose. Find out more at http://dearnobodydiary.com non-fiction/ YA
